Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018 Read more about Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May Read more about Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018 Read more about Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March Read more about Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March
Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors Read more about Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors
Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference Read more about Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock